Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4525 Target Snapshot

Serine/threonine-protein kinase 17A · SINGLE PROTEIN · Homo sapiens

1,517Compounds
299Assays
13Approved Drugs
959.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q9UEE5. Use UniProt Q9UEE5 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q9UEE5 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Serine/threonine-protein kinase 17A as ChEMBL target CHEMBL4525, mapped to UniProt Q9UEE5. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Serine/threonine-protein kinase 17A
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4525
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9UEE5
Serine/threonine-protein kinase 17A
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Serine/threonine-protein kinase 17A is the right protein anchor across sources, using UniProt Q9UEE5 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSerine/threonine-protein kinase 17A
UniProt AccessionQ9UEE5
Component TypeProtein
Sequence Length414 aa

Serine/threonine-protein kinase 17A

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Serine/threonine-protein kinase 17A, mapped to UniProt Q9UEE5. Sequence length is 414 aa.

Mapped IDQ9UEE5
Review nameSerine/threonine-protein kinase 17A
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

13
Approved
5
Phase III
10
Phase II
8
Phase I
Assay Mix

Activity Type Distribution

IC50204.0
KI593.0
KD162.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL535 9.0 Kd 1.0 Approved
CHEMBL1980995 8.6 Ki 2.512 Preclinical
CHEMBL1908397 8.54 Kd 2.9 Preclinical
CHEMBL1984548 8.5 Ki 3.162 Preclinical
CHEMBL1983111 8.5 Ki 3.162 Preclinical
CHEMBL603469 8.47 Kd 3.4 Clinical
CHEMBL1973540 8.4 Ki 3.981 Preclinical
CHEMBL5085430 8.35 IC50 4.47 Preclinical
CHEMBL3334979 8.31 Kd 4.9 Preclinical
CHEMBL4435393 8.3 Kd 5.0 Preclinical
Distribution

pChEMBL Value Distribution

31
5.0
87
5.5
95
6.0
88
6.5
75
7.0
86
7.5
17
8.0
4
8.5
3
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

FEDRATINIB
CHEMBL1287853
Approved 2019
NERATINIB
CHEMBL180022
Approved 2017
ABEMACICLIB
CHEMBL3301610
Approved 2017
NINTEDANIB
CHEMBL502835
Approved 2014
SUNITINIB
CHEMBL535
Approved 2006
Assay Landscape

Assay Landscape

299
Total Assays
260
Tested Compounds
2
Assay Types
Binding — 298 assays, 179 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 231 147 6.8
assay format 46 14 7.5
cell-based format 21 18 6.5
Functional — 1 assays, 260 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 260 6.5

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine